C43
Conditions
Interventions
Group 1: The study includes adult patients (=18 years) with solid tumors, such as melanomas including uveal melanomas, and gynecological tumors (ovarian cancer, endometrial cancer), who show tumor pro
Sponsors
Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Diagnosis of a solid tumor disease, including melanomas (such as uveal melanomas) and gynecological tumors (ovarian cancer, endometrial cancer) - Tumor progression after cell therapy - Subsequent treatment with immunotherapy - Availability of blood samples from routine diagnostics (retrospective part) - Willingness to participate in prospective blood collection (prospective part)
Exclusion criteria
Exclusion criteria: - Lack of follow-up or insufficient clinical documentation - No tumor progression after cell therapy - No subsequent immunotherapy - Contraindications for additional blood collection (e.g., severe hematological disorders) - Refusal to participate in the prospective part of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response (CR/PR/SD vs. PD according to RECIST 1.1) to immune checkpoint inhibitor (ICI) therapy within 30 days (±5 days) in patients with progressive disease after prior cell therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between changes in the immune signature and the TCR T-cell repertoire with clinical response to cell therapy and ICI, as well as with progression-free survival and overall survival. | — |
Countries
Germany
Contacts
Public ContactElisabeth Tregel
Charité - Universitätsmedizin Berlin
Outcome results
None listed